Trial | NCT00300404  Report issue

Title

Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    40
We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection. As TG modulates neurotransmitter metabolism affecting serotonin and dopamine we hypothesize that this chronic persistent infection might play a role for depressive and psychotic symptomatology. Therefore, on the basis of an ex juvantibus approach, specific anti TG medication might further improve psychiatric symptomatology in affected patients. This is investigated in a double-blind, placebo-controlled, randomized treatment trial.
Study Started
Jan 31
2002
Study Completion
Sep 30
2005
Last Update
May 22
2006
Estimate

Drug daraprim

Drug pyrimethamine

Drug folinic acid

Criteria 

Inclusion Criteria:

Schizophrenia or Major Depression
Both genders
Adult
Patients are able to give informed consent

Exclusion Criteria:

Additional diagnosis of substance abuse/dependency
Continuous treatment with medication not compatible with study medication
Medical status not compatible with study medication
Any condition that increases study risk considerably
Pregnancy, nursing
No Results Posted